April to June

• Net sales amounted to MSEK 0.1 (0)

• Net loss was MSEK -3.7 (-6.1), corresponding to earnings per share of SEK -0.06 (-0.10)

• Cash flow after financing activities amounted to MSEK -4.2 (-6.8)

• Cash amounted to MSEK 5.2 (29.6), compared to MSEK 17.8 on 31 December 2022

January to June

• Net sales amounted to MSEK 0.1 (0)

• Net loss was MSEK -10.8 (-14.5), corresponding to earnings per share of SEK -0.18 (-0.24)

• Cash flow after financing activities amounted to MSEK -12.6 (-15.7)

Significant events during January – June

• In February, the milestone Clean file was reached in PHSU05.

• In April the results from the company's Phase II study PHSU05 were announced. No clear differences in the efficacy on reducing the scarring were observed between ensereptide and placebo.

• In May, the company received a limited capital adequacy guarantee (Sw:” kapitaltäckningsgaranti”) to cover for working capital needs for the remainder of 2023.

• In June, the company informed that a number of measures had been taken to reduce the Company's costs, which included the discontinuation of the ensereptide project and the termination of the Company's key personnel.

Events after the reporting period

• In August it was reported that Promore engages Erik Penser Bank as liquidity provider.

” The first six months of this year has been activity intense and strategically challenging.”

Jonas Ekblom, President, and CEO of Promore Pharma